Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Citigroup is a globally important bank with FY2025 revenue of $85.2 billion, Q1 2026 revenue of $24.6 billion and $1.45 trillion of deposits, but the thesis depends on deposit stability, credit, capital and simplification execution.
Tag facets appear after tag usage counts are rebuilt.
Pfizer reported FY2025 revenue of $62.6 billion and Q1 2026 revenue of $14.5 billion. The thesis depends on portfolio durability, oncology integration, patent cliffs, operating cash flow, debt capacity and pipeline execution.
OpenHims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.
OpenHIMS Q1 met the revenue test and raised revenue guidance, but lower margins and reduced adjusted EBITDA guidance keep the thesis conditional.
OpenHims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.
OpenBank of America reported FY2025 revenue of $113.1 billion, FY2025 net income of $30.5 billion and Q1 2026 net income of $8.6 billion. The thesis is deposit durability, capital discipline and credit quality through the rate cycle.
OpenAssured Guaranty is a financial guaranty insurer with Q1 2026 new-business growth, record adjusted book value per share and a long buyback record, but the equity case still depends on ratings strength, insured-credit losses, PREPA and disciplined capital alloc
OpenAGNC is a leveraged Agency MBS mortgage REIT. Q1 2026 spread income covered the common dividend, but tangible book value fell and the common equity remains tied to mortgage spreads, repo funding, hedge performance and leverage.
OpenAgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
OpenFarmer Mac is compounding a record rural-credit book with strong spread income and capital headroom, but AGM holders own non-voting common in a highly levered GSE whose thesis depends on funding access, agricultural credit quality, policy treatment and discipl
OpenAGM.A is Farmer Mac's Class A voting common stock, with real board-election rights for eligible non-Farm Credit System financial institutions and the same declared common dividend as AGM, but ownership restrictions, narrow holder eligibility, related-party con
Openagilon health turned in a stronger Q1 after a brutal FY2025 reset, but the thesis still depends on whether member exits, payor discipline, ACO contribution and CEO execution can hold up against Medicare Advantage medical-cost trend.
OpenAegon is trying to simplify into a U.S.-centered Transamerica story by 2028, with FY2025 capital generation, WFG growth, legacy-risk cleanup, and a GBP 2.0 billion UK sale all pointing in the same direction.
OpenEnact is profitable, overcapitalized against PMIERs, and returning cash through dividends and buybacks, but the public-company thesis still runs through mortgage credit, GSE rules, housing affordability, reinsurance markets, and Genworth's 81% control.
OpenOfficial-source baseline for Ameris Bancorp using SEC submissions, SEC company facts, the FY2025 10-K, Q1 FY2026 10-Q, Q1 2026 filed earnings release and presentation, proxy materials, and FDIC industry context.
OpenAclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
OpenArbor's agency servicing platform gives the mortgage REIT a fee engine, but Q1 2026 still leaves investors underwriting loan modifications, foreclosures, REO impairments, leverage, and dividend coverage.
OpenOfficial-source baseline for AbbVie using SEC submissions, FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, FY2025 results exhibit, proxy materials, annual meeting results, debt filings, and official peer filings.
OpenACNB looks like a sleepy community bank until the filing trail shows a post-Traditions balance sheet reset, a 4.46% Q1 margin, low reported credit stress, and a board returning capital through a higher dividend, a special dividend, and a new buyback.
OpenOfficial-source baseline for Acadian Asset Management using SEC submissions, SEC XBRL companyfacts, the FY2025 10-K, Q1 FY2026 10-Q, Q1 FY2026 earnings presentation and 8-K, 2026 proxy, and competitor filings.
OpenSigned-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Tag facets appear after tag usage counts are rebuilt.